佐竹マルチミクス Company Profile

Our Bio Division will be relocating its office starting April 3rd due to business expansion. New Address: 3-12-18 Kamiaoki, Kawaguchi City, Saitama Prefecture, 333-0844 Room 502, Saitama Industrial Technology Comprehensive Center, SKIP City Phone: 048-471-9202 For more details, please see the news release in the related links.

The biotech venture company Megakaryon Corporation has successfully completed the first administration of a clinical trial in which platelets made from iPS cells were transfused to a patient. Our company is conducting joint research and development of a culture device that enables mass production of iPS platelets for the project being advanced by Megakaryon, achieving high-efficiency production using single-use bioreactors. For more details, please see the news release in the related links.

We are pleased to announce that we have completed the introduction of a single-use automated culture system for the manufacturing of clinical trial products at Helios, Inc.'s cell processing facility, in collaboration with Helios, a biotech venture developing function-enhanced NK (natural killer) cells derived from human iPS cells (gene-edited NK cells derived from human iPS cells) for large-scale culture research and development. In this initiative, Helios has successfully established a feeder-free culture system in a fully closed system for the entire process, achieving a target culture of 100 billion cells per batch. Trial operations will begin soon, aiming for early administration to patients. For more details, please refer to the news release linked in the related links.